NCT00333112

Brief Summary

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
398

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started May 2006

Shorter than P25 for phase_4

Geographic Reach
1 country

74 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2006

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 1, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 2, 2006

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2007

Completed
Last Updated

September 18, 2014

Status Verified

September 1, 2014

Enrollment Period

8 months

First QC Date

June 1, 2006

Last Update Submit

September 17, 2014

Conditions

Keywords

Treatment OutcomeUrologySolifenacin succinateUrinary Incontinence

Outcome Measures

Primary Outcomes (1)

  • Change in micturitions per 24 hours from baseline to end of treatment

    18 weeks

Secondary Outcomes (1)

  • Change in urgency episodes per 24 hours from baseline to end of treatment

    18 weeks

Study Arms (2)

1

EXPERIMENTAL
Drug: solifenacin succinateDrug: tamsulosin

2

PLACEBO COMPARATOR
Drug: tamsulosinDrug: placebo

Interventions

Oral

Also known as: Vesicare®, YM905
1

oral

12

oral

2

Eligibility Criteria

Age45 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Symptoms of Overactive Bladder (OAB)

You may not qualify if:

  • Current use of antimuscarinic therapy
  • Evidence of a urinary tract infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (74)

Unknown Facility

Birmingham, Alabama, 35209, United States

Location

Unknown Facility

Phoenix, Arizona, 85050, United States

Location

Unknown Facility

Tuscon, Arizona, 85712, United States

Location

Unknown Facility

Atherton, California, 94027, United States

Location

Unknown Facility

Beverly Hills, California, 90211, United States

Location

Unknown Facility

Buena, California, 90620, United States

Location

Unknown Facility

Buena Park, California, 90320, United States

Location

Unknown Facility

Carmichael, California, 95608, United States

Location

Unknown Facility

Culver City, California, 90232, United States

Location

Unknown Facility

Fresno, California, 93720, United States

Location

Unknown Facility

Mission Hills, California, 92084, United States

Location

Unknown Facility

Modesto, California, 95350, United States

Location

Unknown Facility

Orange, California, 92869, United States

Location

Unknown Facility

San Bernardino, California, 92404, United States

Location

Unknown Facility

San Diego, California, 92108, United States

Location

Unknown Facility

Torrance, California, 90505, United States

Location

Unknown Facility

Aurora, Colorado, 80012, United States

Location

Unknown Facility

Denver, Colorado, 80210, United States

Location

Unknown Facility

Wheat Ridge, Colorado, 80033, United States

Location

Unknown Facility

Danbury, Connecticut, 06708, United States

Location

Unknown Facility

Clearwater, Florida, 33761, United States

Location

Unknown Facility

Daytona Beach, Florida, 32114, United States

Location

Unknown Facility

Fort Myers, Florida, 33908, United States

Location

Unknown Facility

New Port Richey, Florida, 34652, United States

Location

Unknown Facility

Orlando, Florida, 32803, United States

Location

Unknown Facility

Orlando, Florida, 32806, United States

Location

Unknown Facility

Pembroke Pines, Florida, 33027, United States

Location

Unknown Facility

Pembroke Pines, Florida, 33028, United States

Location

Unknown Facility

Tallahassee, Florida, 32308, United States

Location

Unknown Facility

Wellington, Florida, 33414, United States

Location

Unknown Facility

Atlanta, Georgia, 30342, United States

Location

Unknown Facility

Blue Ridge, Georgia, 30513, United States

Location

Unknown Facility

Marietta, Georgia, 30060, United States

Location

Unknown Facility

Roswell, Georgia, 30076, United States

Location

Unknown Facility

Sandy Springs, Georgia, 30328, United States

Location

Unknown Facility

Snellville, Georgia, 30078, United States

Location

Unknown Facility

Coeur d'Alene, Idaho, 83814, United States

Location

Unknown Facility

Evansville, Indiana, 47714, United States

Location

Unknown Facility

Wichita, Kansas, 67207, United States

Location

Unknown Facility

Shreveport, Louisiana, 71106, United States

Location

Unknown Facility

Boston, Massachusetts, 02115, United States

Location

Unknown Facility

Watertown, Massachusetts, 02472, United States

Location

Unknown Facility

Grand Rapids, Michigan, 49544, United States

Location

Unknown Facility

Jackson, Mississippi, 39202, United States

Location

Unknown Facility

West Orange, New Jersey, 07052, United States

Location

Unknown Facility

Endwell, New York, 13760, United States

Location

Unknown Facility

Garden City, New York, 11530, United States

Location

Unknown Facility

New York, New York, 10016, United States

Location

Unknown Facility

New York, New York, 10021, United States

Location

Unknown Facility

Orchard Park, New York, 14127, United States

Location

Unknown Facility

Poughkeepsie, New York, 12601, United States

Location

Unknown Facility

Rochester, New York, 14642, United States

Location

Unknown Facility

Concord, North Carolina, 28025, United States

Location

Unknown Facility

Hickory, North Carolina, 28601, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27103, United States

Location

Unknown Facility

Cincinnati, Ohio, 45212, United States

Location

Unknown Facility

Cincinnati, Ohio, 45249, United States

Location

Unknown Facility

Bethany, Oklahoma, 73008, United States

Location

Unknown Facility

Norman, Oklahoma, 73071, United States

Location

Unknown Facility

Springfield, Oregon, 97477, United States

Location

Unknown Facility

Bala-Cynwyd, Pennsylvania, 19004, United States

Location

Unknown Facility

Bensalem, Pennsylvania, 19020, United States

Location

Unknown Facility

Camp Hill, Pennsylvania, 17011, United States

Location

Unknown Facility

Lancaster, Pennsylvania, 17604, United States

Location

Unknown Facility

Uniontown, Pennsylvania, 15401, United States

Location

Unknown Facility

Mt. Pleasant, South Carolina, 29464, United States

Location

Unknown Facility

Simpsonville, South Carolina, 29681, United States

Location

Unknown Facility

Nashville, Tennessee, 37203, United States

Location

Unknown Facility

Houston, Texas, 77024, United States

Location

Unknown Facility

Ogden, Utah, 84403, United States

Location

Unknown Facility

Salt Lake City, Utah, 84121, United States

Location

Unknown Facility

Virginia Beach, Virginia, 23454, United States

Location

Unknown Facility

Mountain Lake Terrace, Washington, 98043, United States

Location

Unknown Facility

Spokane, Washington, 99202, United States

Location

Related Publications (1)

  • Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009 Dec;182(6):2825-30. doi: 10.1016/j.juro.2009.08.023. Epub 2009 Oct 17.

    PMID: 19837435BACKGROUND

MeSH Terms

Conditions

Urinary Incontinence

Interventions

Solifenacin SuccinateTamsulosin

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

QuinuclidinesHeterocyclic Compounds, Bridged-RingHeterocyclic CompoundsTetrahydroisoquinolinesIsoquinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingBenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur Compounds

Study Officials

  • Astellas US Medical Information

    Astellas Pharma US, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2006

First Posted

June 2, 2006

Study Start

May 1, 2006

Primary Completion

January 1, 2007

Study Completion

January 1, 2007

Last Updated

September 18, 2014

Record last verified: 2014-09

Locations